Based on these findings, we explored the plasma levels of FASN and DHCR24 as potential biomarkers in melanoma patients and tested the association between the expression levels of the two enzymes and the different clinical-demographic features of melanoma patients, including blood total CHOL, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and TG. This evidence concerns the gene FASN and melanoma.